Lisata Therapeutics, Inc. (LSTA)

NASDAQ: LSTA · IEX Real-Time Price · USD
3.19
-0.36 (-10.14%)
Dec 6, 2022 2:59 PM EST - Market open
-10.14%
Market Cap 27.90M
Revenue (ttm) n/a
Net Income (ttm) -55.03M
Shares Out 4.75M
EPS (ttm) -12.38
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 6,599
Open 3.62
Previous Close 3.55
Day's Range 3.19 - 3.62
52-Week Range 3.19 - 17.1
Beta 0.97
Analysts Buy
Price Target 30.60 (+859.2%)
Earnings Date Nov 10, 2022

About LSTA

Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kid... [Read more]

Industry Biotechnology
Founded 1980
CEO David Mazzo
Employees 27
Stock Exchange NASDAQ
Ticker Symbol LSTA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for LSTA stock is "Buy." The 12-month stock price forecast is 30.6, which is an increase of 859.25% from the latest price.

Price Target
$30.6
(859.25% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Lisata Therapeutics Announces Participation in Upcoming Conferences in November 2022

BASKING RIDGE, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for t...

4 weeks ago - GlobeNewsWire

Lisata Therapeutics Announces Participation in Upcoming Conferences in October 2022

BASKING RIDGE, N.J., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies fo...

2 months ago - GlobeNewsWire

Caladrius Biosciences and Cend Therapeutics Announce Closing of Merger and the Emergence of Lisata Therapeutics

Company to commence trading on The Nasdaq Capital Market under Ticker Symbol “LSTA”

Other symbols: CLBS
2 months ago - GlobeNewsWire

Caladrius Biosciences Announces Approval of Merger and Name Change to Lisata Therapeutics

All Merger-related proposals approved at the Annual Meeting of Stockholders All Merger-related proposals approved at the Annual Meeting of Stockholders

Other symbols: CLBS
2 months ago - GlobeNewsWire

Caladrius Biosciences' Prospective Merger Partner, Cend Therapeutics, Announces Collaboration Agreement with Roche to...

Study to be part of Roche's Morpheus Platform designed to enable more rapid and efficient development of novel cancer immunotherapy combinations

Other symbols: CLBS
3 months ago - GlobeNewsWire

Caladrius Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Merger with Cend Therapeutics remains on track to close in the third quarter of 2022, subject to stockholder approval, resulting in the formation of Lisata Therapeutics

Other symbols: CLBS
4 months ago - GlobeNewsWire

CALADRIUS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of C...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Caladrius Biosci...

Other symbols: CLBS
4 months ago - Business Wire

Caladrius Biosciences Completes Enrollment in Phase 1b Study of CLBS201 for the Treatment of Diabetic Kidney Disease

Top-line data from all subjects expected by the first quarter of 2023 Top-line data from all subjects expected by the first quarter of 2023

Other symbols: CLBS
4 months ago - GlobeNewsWire

Caladrius Biosciences Announces Merger Partner, Cend Therapeutics, has Treated First Patient in Phase 2b Trial of CEN...

BASKING RIDGE, N.J., June 09, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development ...

Other symbols: CLBS
5 months ago - GlobeNewsWire

Caladrius Biosciences to Present at the BIO International Convention 2022

BASKING RIDGE, N.J., June 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development ...

Other symbols: CLBS
5 months ago - GlobeNewsWire

Caladrius Biosciences Provides Update on Phase 2b FREEDOM Trial of XOWNA® in Coronary Microvascular Dysfunction

Interim analysis to be conducted following enrollment suspension in the double-blind, randomized, placebo-controlled clinical trial

Other symbols: CLBS
6 months ago - GlobeNewsWire

Caladrius Biosciences to Present at the H.C. Wainwright Global Investment Conference

BASKING RIDGE, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development o...

Other symbols: CLBS
6 months ago - GlobeNewsWire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates GTYH, CLBS, IGNY, TWTR

NEW YORK , May 9, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of ...

Other symbols: CLBSGTYHTWTR
6 months ago - PRNewsWire

CALADRIUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of C...

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Caladrius Biosci...

Other symbols: CLBS
7 months ago - Business Wire

Caladrius Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update

Signs definitive merger agreement with Cend Therapeutics along with immediate investment and collaboration agreements

Other symbols: CLBS
7 months ago - GlobeNewsWire

Caladrius Biosciences, Inc

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Caladrius Biosciences, Inc. MergerWilmington, Delaware--(Newsfile Corp. - April 29, 2022) - Rigrodsky Law, P.A. is investigating Caladrius Bioscie...

Other symbols: CLBS
7 months ago - Newsfile Corp

Caladrius Biosciences to Host First Quarter 2022 Financial Results Conference Call on Thursday, May 5, 2022, at 4:30 ...

BASKING RIDGE, N.J., April 28, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development...

Other symbols: CLBS
7 months ago - GlobeNewsWire

CLBS Stock Alert: Halper Sadeh LLP Is Investigating Whether the Merger of Caladrius Biosciences, Inc. Is Fair to Shar...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, an investor rights law firm, is investigating whether the merger of Caladrius Biosciences, Inc. (NASDAQ: CLBS) and Cend Therapeutics, Inc. is fair to Caladri...

Other symbols: CLBS
7 months ago - Business Wire

Caladrius Biosciences To Merge With Privately-Held Cend Therapeutics

Caladrius Biosciences Inc (NASDAQ: CLBS) and privately-held Cend Therapeutics Inc have agreed to merge in an all-stock approximate "merger of equals" transaction approved by the Boards of Directors of e...

Other symbols: CLBS
7 months ago - Benzinga

Caladrius Biosciences and Cend Therapeutics Announce Definitive Merger Agreement

Combined company to be renamed Lisata Therapeutics upon transaction closing

Other symbols: CLBS
7 months ago - GlobeNewsWire

Caladrius Biosciences Treats First Patient in the Phase 1b Trial of CLBS201 for the Treatment of Diabetic Kidney Disease

BASKING RIDGE, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development...

Other symbols: CLBS
7 months ago - GlobeNewsWire

Caladrius Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Conference call begins today at 4:30 p.m. Eastern time Conference call begins today at 4:30 p.m. Eastern time

Other symbols: CLBS
8 months ago - GlobeNewsWire

Caladrius Biosciences to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call on Tuesday, March 2...

BASKING RIDGE, N.J., March 15, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development...

Other symbols: CLBS
8 months ago - GlobeNewsWire

Caladrius Biosciences Receives $2.3 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certif...

BASKING RIDGE, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development...

Other symbols: CLBS
9 months ago - GlobeNewsWire

Caladrius Biosciences to Present at the BIO CEO & Investor Conference

BASKING RIDGE, N.J., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development ...

Other symbols: CLBS
9 months ago - GlobeNewsWire